News

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with isatuximab plus VRd vs VRd alone in patients with newly diagnosed, transplant-ineligible multiple myeloma.

Xiuning Le, MD, PhD, delved into the background, findings, and next steps of the SOHO-01 study.

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented at the 2024 ESMO Congress.

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.

The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute lymphoblastic leukemia treatment.

Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2-overexpressing cancers.

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.

Combination therapies in CLL are generating excitement with ongoing trials that could expand standard practice for the future.

In an interview with Targeted Oncology, Sergio A. Giralt, MD, discussed the evolving role of transplant in myelodysplastic syndromes.

CheckMate-9ER post hoc analysis suggests certain sugar molecules on blood proteins may predict how well niovlumab and cabozantinib in kidney cancer treatment works.

The REMARK trial aims to assess the safety and efficacy of RVU120 in patients with lower-risk myelodysplastic syndromes.

Francis P. Worden, MD, discusses a real-world study evaluating lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer.

The phase 2 BRACELET-1 trial demonstrated that the combination of pelareorep and paclitaxel significantly improved outcomes for patients with HR-positive/HER2-negative metastatic breast cancer.

The GigaPath AI model was highlighted for its advanced capabilities in predicting cancer mutations and tumor mutation burden, including those in lung cancer and other malignancies.

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading experts.

CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in the phase 1 MAST trial.

Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic leukemia and some of the available treatment options in this space.

The combination of lenvatinib and pembrolizumab showed promising results in treating recurrent endometrial carcinoma, demonstrating significant antitumor activity and improved survival rates compared to standard therapy.

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination with azacitidine and venetoclax in AML.

Follow-up results from the POSITIVE trial showed that breastfeeding is achievable for patients with HR-positive breast cancer who conceived during a break from endocrine therapy.

Targeted therapy, as determined by genomic profiling, outperformed standard of care in patients with pretreated metastatic cancers.

Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.

Neoadjuvant chemotherapy prior to surgery and postoperative radiation therapy could improve organ preservation in patients with T3 and T4a nasal and paranasal sinus squamous cell carcinoma.

A phase 2 trial of ipilimumab plus nivolumab has met its primary end point of 12-month overall survival rate in non-clear cell renal cell carcinoma.

Fianlimab combined with cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma, regardless of LAG-3 or PD-L1 expression.

The combination of benmelstobart with anlotinib led to efficacy improvements in patients with advanced renal cell carcinoma vs sunitinib.